Prospective randomized phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) patients (pts) with nonsquamous (non SCC) histologic type: NAVoTRIAL01—Preliminary results.

Jaafar Bennouna,Libor Havel,Maciej Krzakowski,Jens Kollmeier,Radj Gervais,Eric Dansin,Monika Serke,Adolfo Favaretto,Manuel Cobo,Aleksandra Szczęsna,Libero Ciuffreda,Jacek Jassem,Mario Nicolini,Rodryg Ramlau,Domenico Amoroso,Barbara Melotti,Teresa Almodovar,Nathalie Vaissiere,Marcello Riggi,Eng-Huat Tan

Prospective randomized phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) patients (pts) with nonsquamous (non SCC) histologic type: NAVoTRIAL01—Preliminary results.

2017

7575 Background: NVBo+P is considered as a standard treatment (trt) in M or LA NSCLC. The recent approval of Pem+P as front line chemotherapy (CT) for non-SCC demonstrates that today, histology cou...

Keywords:

Vinorelbine
Pathology
Cell
Pemetrexed
Oncology
Cisplatin
Lung cancer
Medicine
Internal medicine
Histology
Chemotherapy
Standard treatment
first line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations